Life Science News

Enochian Biosciences (OTCQB:ENOB), a biopharmaceutical company developing potentially curative and preventative gene-modified cell therapy platforms to transform the lives of persons living with HIV and cancer patients, today announced that the Company has received confirmation that its application to list the Company’s common stock on the NASDAQ Capital Market has been approved by the NASDAQ …

Enochian Biosciences (OTCQB:ENOB), a biopharmaceutical company developing potentially curative and preventative gene-modified cell therapy platforms to transform the lives of persons living with HIV and cancer patients, today announced that the Company has received confirmation that its application to list the Company’s common stock on the NASDAQ Capital Market has been approved by the NASDAQ Stock Market.

As quoted in the press release:

Enochian’s common stock is expected to begin trading on the NASDAQ Capital Market on December 10, 2018 under the ticker symbol “ENOB.” The Company’s common stock will continue to trade on the Over-the-Counter Bulletin Board under the ticker symbol “ENOB” until market close on December 7, 2018.

“We believe that the uplisting to NASDAQ will help attract institutional investors, broaden our shareholder base and enhance trading liquidity. We are excited about this milestone and look forward to progressing our gene-modified cell therapy platform to treat infectious disease and cancer patients,” stated Eric Leire, MD, CEO.

Click here to read the full press release.

Featured

MARKETS

Markets
TSX21184.95+279.67
TSXV807.38+12.73
DOW34061.06+932.27
S&P 5004300.17+124.69
NASD12964.86+401.10
ASX7316.20-30.80

COMMODITIES

Commodities
Gold1901.08+7.14
Silver23.14+0.14
Copper4.42+0.08
Palladium2280.50+24.50
Platinum1003.00+5.00
Oil108.01+0.20
Heating Oil4.21+0.01
Natural Gas8.54+0.12

DOWNLOAD FREE REPORTS

×